By Dr Mark William Donoghoe

Journal articles

Tarnow-Mordi W; Stenson B; Kirby A; Juszczak E; Donoghoe M; Deshpande S; Morley C; King A; Doyle LW; Fleck BW; Davis PG; Halliday HL; Hague W; Cairns P; Darlow BA; Fielder AR; Gebski V; Marlow N; Simmer K; Tin W; Ghadge A; Williams C; Keech A; Wardle SP; Kecskes Z; Kluckow M; Gole G; Evans N; Malcolm G; Luig M; Wright I; Stack J; Tan K; Pritchard M; Gray PH; Morris S; Headley B; Dargaville P; Simes RJ; Brocklehurst P, 2016, 'Outcomes of two trials of oxygen-saturation targets in preterm infants', New England Journal of Medicine, 374, pp. 749 - 760, http://dx.doi.org/10.1056/NEJMoa1514212

Donoghoe MW; Marschner IC, 2015, 'Flexible regression models for rate differences, risk differences and relative risks', International Journal of Biostatistics, 11, pp. 91 - 108, http://dx.doi.org/10.1515/ijb-2014-0044

Darlow BA; Marschner SL; Donoghoe M; Battin MR; Broadbent RS; Elder MJ; Hewson MP; Meyer MP; Ghadge A; Graham P; McNeill NJ; Kuschel CA; Tarnow-Mordi WO, 2014, 'Randomized controlled trial of oxygen saturation targets in very preterm infants: Two year outcomes', Journal of Pediatrics, 165, pp. 30 - e2, http://dx.doi.org/10.1016/j.jpeds.2014.01.017

Donoghoe MW; Marschner IC, 2014, 'Stable computational methods for additive binomial models with application to adjusted risk differences', Computational Statistics and Data Analysis, 80, pp. 184 - 196, http://dx.doi.org/10.1016/j.csda.2014.06.019

Blinman P; Gainford C; Donoghoe M; Martyn J; Blomfield P; Grant P; Kichenadasse G; Vaughan M; Brand A; Shannon C; Gebski V; Stockler M; Friedlander M, 2013, 'Feasibility, acceptability and preferences for intraperitoneal chemotherapy with paclitaxel and cisplatin after optimal debulking surgery for ovarian and related cancers: An ANZGOG study', Journal of Gynecologic Oncology, 24, pp. 359 - 366, http://dx.doi.org/10.3802/jgo.2013.24.4.359

Stenson BJ; Tarnow-Mordi WO; Darlow BA; Simes J; Juszczak E; Askie L; Battin M; Bowler U; Broadbent R; Cairns P; Davis PG; Deshpande S; Donoghoe M; Doyle L; Fleck BW; Ghadge A; Hague W; Halliday HL; Hewson M; King A; Kirby A; Marlow N; Meyer M; Morley C; Simmer K; Tin W; Wardle SP; Brocklehurst P, 2013, 'Oxygen saturation and outcomes in preterm infants', New England Journal of Medicine, 368, pp. 2094 - 2104, http://dx.doi.org/10.1056/NEJMoa1302298

Chan KH; O’Connell RL; Sullivan DR; Hoffmann LS; Rajamani K; Whiting M; Donoghoe MW; Vanhala M; Hamer A; Yu B; Stocker R; Ng MKC; Keech AC, 2013, 'Plasma total bilirubin levels predict amputation events in type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study', Diabetologia, 56, pp. 724 - 736, http://dx.doi.org/10.1007/s00125-012-2818-4

Stanton K; Rao S; Assimes T; Wang B; McGee S; Harada R; Wilson A; Narasimhan B; Donoghoe M; Olin J; Cooke J; Ng M, 2012, 'Asymmetric Dimethylarginine (ADMA) Levels Correlate with Peripheral Vascular Disease Severity but not Coronary Artery Disease', Heart, Lung and Circulation, 21, pp. S11 - S11, http://dx.doi.org/10.1016/j.hlc.2012.05.034

Ting R; Keech A; Drury P; Donoghoe M; Hedley J; Jenkins AJ; Davis T; Lehto S; Celermajer DS; Simes J; Kushwin R; Stanton K; Suranyi MG, 2012, 'Benefits and safety of long-term fenofibrate therapy in people with type 2 diabetes and renal impairment', Diabetes Care, 35, pp. 218 - 225, http://dx.doi.org/10.2337/dc11-1109

Scott R; Donoghoe M; Watts GF; O'Brien R; Pardy C; Taskinen MR; Davis TME; Colman PG; Manning P; Fulcher G; Keech AC, 2011, 'Impact of metabolic syndrome and its components on cardiovascular disease event rates in 4900 patients with type 2 diabetes assigned to placebo in the field randomised trial', Cardiovascular Diabetology, 10, http://dx.doi.org/10.1186/1475-2840-10-102

Sullivan D; Forder P; Simes J; Whiting M; Kritharides L; Merrifield A; Donoghoe M; Colman PG; Graham N; Haapamäki H; Keech A, 2011, 'Associations between the use of metformin, sulphonylureas, or diet alone and cardiovascular outcomes in 6005 people with type 2 diabetes in the FIELD study', Diabetes Research and Clinical Practice, 94, pp. 284 - 290, http://dx.doi.org/10.1016/j.diabres.2011.07.028

Joly F; Ray-Coquard I; Fabbro M; Donoghoe M; Boman K; Sugimoto A; Vaughan M; Reinthaller A; Vergote I; Ferrandina G; Dell'Anna T; Huober J; Pujade-Lauraine E, 2011, 'Decreased hypersensitivity reactions with carboplatin-pegylated liposomal doxorubicin compared to carboplatin-paclitaxel combination: Analysis from the GCIG CALYPSO relapsing ovarian cancer trial', Gynecologic Oncology, 122, pp. 226 - 232, http://dx.doi.org/10.1016/j.ygyno.2011.04.019

Davis TME; Ting R; Best JD; Donoghoe MW; Drury PL; Sullivan DR; Jenkins AJ; O'Connell RL; Whiting MJ; Glasziou PP; Simes RJ; Kesäniemi YA; Gebski VJ; Scott RS; Keech AC, 2011, 'Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: The Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study', Diabetologia, 54, pp. 280 - 290, http://dx.doi.org/10.1007/s00125-010-1951-1

Ting R; Davis T; Drury P; Donoghoe M; Rajamani K; Best J; Kesaniemi Y; Keech A, 2011, 'Cardiovascular Risk, Renal Status and Fenofibrate Safety in the FIELD Study', Heart, Lung and Circulation, 20, pp. S202 - S202, http://dx.doi.org/10.1016/j.hlc.2011.05.497

Donoghoe MW; Gebski V, 2011, 'Impact of the censoring distribution on time-to-event problems in the presence of competing risks', Trials, 12, http://dx.doi.org/10.1186/1745-6215-12-s1-a140

Ting R-D; Davis TME; Drury PL; Donoghoe M; Rajamani K; Best JD; Kesaniemi YA; Keech AC, 2010, 'CARDIOVASCULAR AND RENAL SAFETY OF FENOFIBRATE IN THE FIELD STUDY', ATHEROSCLEROSIS SUPPLEMENTS, 11, pp. 219 - 219, http://dx.doi.org/10.1016/S1567-5688(10)71044-8

Rajamani K; Donoghoe M; Li L; Ting R-D; Colman P; Scott R; Laakso M; Keech A, 2010, 'FENOFIBRATE REDUCES PERIPHERAL NEUROPATHY IN TYPE 2 DIABETES: THE FENOFIBRATE INTERVENTION AND EVENT LOWERING IN DIABETES (FIELD) STUDY', ATHEROSCLEROSIS SUPPLEMENTS, 11, pp. 219 - 220, http://dx.doi.org/10.1016/S1567-5688(10)71046-1

Sullivan D; Donoghoe M; Simes J; George J; Keech T, 2009, 'Abstract: P496 LONG-TERM FENOFIBRATE USE IS ASSOCIATED WITH REDUCED PREVALENCE OF LIVER ENZYME ELEVATION IN THE FIELD STUDY', Atherosclerosis Supplements, 10, pp. e809 - e809, http://dx.doi.org/10.1016/s1567-5688(09)70791-3

Conference Papers

McLoone J; Signorelli C; Wakefield C; Donoghoe M; Thornton-Benko E; Johnston K; Baldwin R; Cohn R, 2024, ''Engage': A novel distance-delivered intervention to support childhood cancer survivorship care', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, pp. 76 - 77

Cohen J; Gohil P; Lovell A; Winkler L; Donoghoe M; Mellett K; Wakefield C, 2023, 'EFFECT OF AN ONLINE NUTRITION INTERVENTION (REBOOT-KIDS) ON THE DIETARY INTAKE OF YOUNG CHILDHOOD CANCER SURVIVOR'S FRUIT AND VEGETABLE INTAKE: A RANDOMISED-CONTROLLED TRIAL', in PEDIATRIC BLOOD & CANCER, WILEY, pp. S531 - S531

Body A; Wakefield C; Vi TTL; Donoghoe M; Bolanos NAF; Anazodo A; Ho C; Grech L; Ahern ES; Segelov E, 2022, 'Patient-reported toxicity and quality of life following Sars-CoV-2 vaccination in adults and children with cancer', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, ELECTR NETWORK, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 03 June 2022 - 07 June 2022

Mitchell P; Siva S; Kok PS; O'Byrne K; Yeung A; Livingstone A; Donoghoe M; Yip S; Stockier MR, 2017, 'NIVORAD: A randomised phase 2 trial of nivolumab and stereotactic ablative body radiotherapy in advanced non-small cell lung cancer, progressing after first or second line chemotherapy.', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, presented at 53rd Annual Clinical Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 02 June 2017 - 07 June 2017, http://dx.doi.org/10.1200/JCO.2017.35.15_suppl.9097

Stanton KM; Rao SD; Assimes T; Wang B-Y; McGee S; Harada RK; Wilson A; Narasimhan B; Donoghoe M; Brown C; Keech A; Olin JW; Cooke JP; Ng MK, 2012, 'Plasma Asymmetric Dimethylarginine Levels Correlate with Peripheral Arterial Disease Severity but not Coronary Artery Disease', in CIRCULATION, LIPPINCOTT WILLIAMS & WILKINS, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000208885006387&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Ting R; Davis TME; Jenkins AJ; Drury PL; Donoghoe MW; Rajamani JK; Kesaniemi AY; Best JD; Keech AC, 2011, 'Association of renal status and cardiovascular risk, and safety of fenofibrate in renal impairment in the FIELD study of 9,795 subjects with type 2 diabetes', in DIABETOLOGIA, SPRINGER, PORTUGAL, Lisbon, pp. S24 - S24, presented at 47th Annual Meeting of the European-Association-for-the-Study-of-Diabetes (EASD), PORTUGAL, Lisbon, 12 September 2011 - 16 September 2011, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000307671300042&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Keech AC; Rajamani JK; Best JD; Hankey G; Donoghoe MW; Li L; Jenkins AJ; Ting R; Davis TME; Phillips P; Barter P, 2011, 'Predictors of peripheral neuropathy and effects of fenofibrate among 9,795 subjects with type 2 diabetes: the fenofibrate intervention and event lowering in diabetes (FIELD) study', in DIABETOLOGIA, SPRINGER, PORTUGAL, Lisbon, pp. S81 - S82, presented at 47th Annual Meeting of the European-Association-for-the-Study-of-Diabetes (EASD), PORTUGAL, Lisbon, 12 September 2011 - 16 September 2011, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000307671300181&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Ting R; Donoghoe M; Jenkins AJ; Hedley J; Rajamani K; Drury PL; Davis TME; Celermajer D; Simes RJ; Keech AC, 2011, 'Benefits and safety of long-term fenofibrate therapy in people with type 2 diabetes mellitus and renal impairment - the FIELD study', in EUROPEAN HEART JOURNAL, OXFORD UNIV PRESS, pp. 323 - 324, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000208702703033&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Jenkins AJ; Whiting M; Sullivan D; Best JD; Barter P; Donoghoe M; Januszewski AS; Karschimkus CS; Blankenberg S; Simes J; Scott R; Laakso M; Taskinen M-R; Keech AC, 2011, 'Inflammation and Oxidative Stress in Type 2 Diabetes Vascular Complications: Predictive Power and Effects of Fenofibrate in the Fenofibrate Intervention and Event Lowering in Diabetes Study', in DIABETES, AMER DIABETES ASSOC, pp. A9 - A9

Rajamani K; Donoghoe M; Li L; Ting R-D; Colman PG; Drury P; Laakso M; Keech AC, 2010, 'Fenofibrate Reduces Peripheral Neuropathy in Type 2 Diabetes: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study', in CIRCULATION, LIPPINCOTT WILLIAMS & WILKINS

Keech AC; Alicia J; Whiting M; Barter P; Sullivan DR; Donoghoe M; Januszewski A; Karschimkus C; Blankenberg S; Simes J; Scott R; Laakso M; Taskinen M-R; Best JD, 2010, 'Novel Cardiovascular Risk Factor Prediction of Cardiovascular Events in the (Type 2 Diabetes) FIELD Study and Effects of Fenofibrate', in CIRCULATION, LIPPINCOTT WILLIAMS & WILKINS, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000208231602961&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Keech A; Drury P; Davis TM; Donoghoe M; Laakso M; Whiting M; Scott R; D'Emden MC, 2009, 'Protection Against Nephropathy With Fenofibrate in Type 2 Diabetes Mellitus: The FIELD Study', in CIRCULATION, LIPPINCOTT WILLIAMS & WILKINS, FL, Orlando, pp. S419 - S420, presented at 82nd Scientific Session of the American-Heart-Association, FL, Orlando, 14 November 2009 - 18 November 2009

Ting R-D; Donoghoe M; Li L-P; Davis TM; O'Connell R; Gebski V; Best JD; Kesaniemi A; Laakso M; Keech AC, 2009, 'Risk Predictors of First Microvascular Complications in Type 2 Diabetes Mellitus: The FIELD Study', in CIRCULATION, LIPPINCOTT WILLIAMS & WILKINS, FL, Orlando, pp. S496 - S496, presented at 82nd Scientific Session of the American-Heart-Association, FL, Orlando, 14 November 2009 - 18 November 2009

Sullivan D; Donoghoe M; Simes J; George J; Keech T, 2009, 'LONG-TERM FENOFIBRATE USE IS ASSOCIATED WITH REDUCED PREVALENCE OF LIVER ENZYME ELEVATION IN THE FIELD STUDY', in ATHEROSCLEROSIS SUPPLEMENTS, ELSEVIER IRELAND LTD, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000207957101492&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Conference Posters

Nowak A; Kok P-S; Livingstone A; Lesterhuis WJ; Yip S; Donoghoe M; Lam W-S; Stockler M, 2017, 'DREAM - A Phase 2 Trial of DuRvalumab with First Line chEmotherApy in Mesothelioma with a Safety Run In', Vol. 12, pp. S1086 - S1087, http://dx.doi.org/10.1016/j.jtho.2016.11.1518

Conference Abstracts

Nagabushan S; Hamayun M; Fardell JE; Donoghoe M; Bland E; Bye A; Jacobson E; Manoharan N; Ziegler DS; McLoone JK; Johnson AM; Cohn RJ, 2023, 'LGG-11. COGNITIVE, ACADEMIC, AND QUALITY OF LIFE OUTCOMES IN SURVIVORS OF PEDIATRIC LOW-GRADE GLIOMA: CHALLENGING THE ‘BENIGN TUMOR’ PERCEPTION', in Neuro-Oncology, Oxford University Press (OUP), Vol. 25, pp. i57 - i58, http://dx.doi.org/10.1093/neuonc/noad073.221

Body A; Wakefield C; Luong VTT; Donoghoe M; Bolanos NAF; Anazodo A; Ho C; Grech L; Ahern ES; Segelov E, 2022, 'Patient-reported toxicity and quality of life following Sars-CoV-2 vaccination in adults and children with cancer.', in Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 40, pp. lba12068 - lba12068, http://dx.doi.org/10.1200/jco.2022.40.17_suppl.lba12068

McLoone J; Signorelli C; Wakefield CE; Donoghoe M; Johnston K; Bell R; Cohn RJ, 2022, 'The 'ENGAGE' program: Effective childhood cancer survivorship care', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, Vol. 18, pp. 80 - 80

Robertson E; Wakefield C; Cohn R; Robert B; Donoghoe M; Ziegler D; Fardell J; Mitchell R; O'Brien T, 2019, 'Delta: A Parent and Patient Decision Aid to Support Clinical Trial Decision-Making in Childhood Cancer', in PEDIATRIC BLOOD & CANCER, WILEY, Vol. 66, pp. S118 - S118, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000488458001090&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Barbour A; O'Rourke N; Chandrasegaram MD; Chua YJ; Kench J; Samra JS; Pavlakis N; Haghighi KS; Yip S; Fawcett J; Donoghoe M; Walker K; Burge ME; Gananadha S; Harris M; Aghmesheh M; Joubert WL; Gebski V; Simes J; Goldstein D, 2015, 'A multicenter, phase II trial of preoperative gemcitabine and nab-paclitaxel for resectable pancreas cancer: The AGITG GAP study.', in Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 33, pp. 4115 - 4115, http://dx.doi.org/10.1200/jco.2015.33.15_suppl.4115

Preprints

Foster C; Donoghoe MW; Battisti A; D'Eugenio F; Harborne K; Venville T; Lagos CDP; Mendel JT; Bagge R; Barsanti S; Bellstedt S; Boecker A; Chen Q; Derkenne C; Ferre-Matteu A; Gjergo E; Gupta A; Muller EGM; Santucci G; Park H-J; Remus R-S; Thater S; Sande JVD; Vaughan S; Brough S; Croom SM; Valenzuela LM; Wisnioski E; Team TMAGPI, 2025, The MAGPI Survey: the kinematic morphology-density relation (or lack thereof) and the Hubble sequence at $z\sim0.3$, https://arxiv.org/abs/2502.16751v1

Spitzer H; Berry S; Donoghoe M; Pelkmans L; Theis FJ, Learning consistent subcellular landmarks to quantify changes in multiplexed protein maps, http://dx.doi.org/10.1101/2022.05.07.490900

Body A; Donoghoe M; Lal L; Wakefield C; Ahern ES; Anazodo A; Bolanos NAF; Padhye B; Downie P; Opat S; Hamad N; Leahy MF; Milch V; Segelov E, Vaccine beliefs, adverse effects, and quality of life in patients with cancer undergoing routine COVID-19 vaccination, http://dx.doi.org/10.1101/2024.06.02.24308345

Back to profile page